Description

Val-Cit-PAB-Exatecan (Val-Cit-PAB-DX8951) is a agent-linker conjugate for ADC. Val-Cit-PAB-Exatecan is composed of a DNA topoisomerase I DX-8951 (HY-13631) and a cathepsin cleavable ADC linker[1].–20°C (Powder, sealed storage, away from moisture and light)-Applications-Cancer-programmed cell death-Formula-C43H49FN8O9-Citation–References-[1]Thomas A, et al. Antibody-drug conjugates for cancer therapy. Lancet Oncol. 2016 Jun;17(6):e254-e262.-CASNumber-2227350-99-2-MolecularWeight-840.90-Compound Purity-99.21-SMILES-CC(C)[C@H](N)C(N[C@@H](CCCNC(N)=O)C(NC(C=C1)=CC=C1COC(N[C@@H]2C3=C4C(C(N5C4)=CC([C@](O)(C(OC6)=O)CC)=C6C5=O)=NC7=CC(F)=C(C)C(CC2)=C73)=O)=O)=O-Research_Area-Cancer-Solubility-10 mM in DMSO-Target-Drug-Linker Conjugates for ADC;Topoisomerase-Isoform-Camptothecins-Pathway-Antibody-drug Conjugate/ADC Related;Cell Cycle/DNA Damage-MCE Product type-ADC Related